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Results of a Prospective Randomized Pharmacokinetic and
Pharmacodynamic InvestigationFrancesco Franchi, MD, Fabiana Rollini, MD, Jung Rae Cho, MD, Mona Bhatti, MD, Christopher DeGroat, MD,
Elisabetta Ferrante, PHD, Elizabeth C. Dunn, RN, Amit Nanavati, MD, Edward Carraway, MD, Siva Suryadevara, MD,
Martin M. Zenni, MD, Luis A. Guzman, MD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PHDABSTRACTOBJECTIVES The goal of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) proﬁles of
escalating ticagrelor loading dose (LD) regimens in primary percutaneous coronary intervention (PPCI).
BACKGROUND Patients with ST-segment elevation myocardial infarction undergoing PPCI frequently have suboptimal
platelet inhibition in the early hours after ticagrelor LD. The use of high ticagrelor LD regimens has been hypothesized to
optimize platelet inhibition in PPCI.
METHODS This was a prospective, randomized study of escalating ticagrelor LD regimens (180 mg, 270 mg, or 360 mg)
in PPCI (N ¼ 52). PK/PD analyses were performed before and 30 min, 1, 2, 4, 8, and 24 h post-LD. PK assessments
included exposure to ticagrelor and its metabolite (AR-C124910XX). PD assessments included P2Y12 reaction units (PRU)
measured by VerifyNow P2Y12 and platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein
(VASP).
RESULTS Platelet reactivity was elevated during the ﬁrst 2 h post-LD. There were no differences in PRU between
groups during the study time course (p ¼ 0.179). There were no signiﬁcant differences in PRU levels across groups at all
time points, except at 1 h (p ¼ 0.017) where platelet reactivity was lowest with a 270-mg LD. No differences were found
between the 180-mg and 360-mg groups (primary endpoint; p > 0.999). High on-treatment platelet reactivity rates
were not different across groups, except at 1 hour (p ¼ 0.038). Parallel PD ﬁndings were observed with VASP-PRI. PK
analysis showed a delay in ticagrelor absorption and generation of AR-C124910XX, irrespective of dose. Although
morphine was associated with a delay in ticagrelor PK/PD, it was not an independent predictor of high on-treatment
platelet reactivity.
CONCLUSIONS ST-segment elevation myocardial infarction patients undergoing PPCI frequently exhibit impaired
response to ticagrelor in the early hours after drug administration, which cannot be overcome by increasing LD regimens.
These PD ﬁndings are largely attributed to an impaired PK proﬁle, indicating a delay in drug absorption compared with
that reported in stable clinical settings. (High Ticagrelor Loading Dose in STEMI; NCT01898442)
(J Am Coll Cardiol Intv 2015;8:1457–67) © 2015 by the American College of Cardiology Foundation.




ARB = angiotensin receptor
blocker
AUC = area under the curve
Cmax = maximal observed
plasma concentration
HPR = high on-treatment
platelet reactivity
LD = loading dose
PD = pharmacodynamic
PK = pharmacokinetic
PPCI = primary percutaneous
coronary intervention
PRI = platelet reactivity index
PRU = P2Y12 reaction units
STEMI = ST-segment elevation
myocardial infarction
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1458T icagrelor is a ﬁrst-in-class cyclopen-tyltriazolopyrimidine, which revers-ibly and directly (without being
metabolized) inhibits the platelet P2Y12
receptor; approximately 30% of ticagrelor-
induced platelet inhibition derives from a
metabolite generated through cytochrome
P450 3A4 metabolism (1,2). Compared with
clopidogrel, ticagrelor has more prompt and
potent antiplatelet effects and reduces, to a
greater extent, atherothrombotic events
including cardiovascular mortality in pa-
tients with acute coronary syndrome (3–5).
Importantly, the beneﬁts of ticagrelor were
shown to be consistent across several sub-
groups, comprising patients with ST-
segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous
coronary intervention (PPCI) (5,6). Recently,
pharmacodynamic (PD) studies assessing
oral P2Y12 inhibitors, including ticagrelor,
have shown a delay in platelet inhibitory ef-
fects in STEMI patients undergoing PPCI
(7–9). In turn, a considerable number ofpatients persist with inadequate platelet inhibition
in the early hours after loading dose (LD) administra-
tion, suggesting the potential need for higher dosing
regimens (8,9). Although pharmacokinetic (PK)
studies conducted in healthy volunteers have shown
that peak plasma concentrations of ticagrelor are
dose-dependent (2), to date there are no studies that
have comprehensively investigated both the PK and
PD effects of higher ticagrelor LD in STEMI patients
undergoing PPCI.
METHODS
PATIENT POPULATION AND STUDY DESIGN. This was
a prospective, randomized, open-label, parallel
design study investigating the PK and PD effects
of escalating LD regimens of ticagrelor in STEMI
patients undergoing PPCI (NCT01898442). All
consecutive patients between 18 and 80 years of age
presenting with a STEMI undergoing PPCI and whoivision of Cardiology, University of Florida College of Medicine-J
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t received February 12, 2015; revised manuscript received Februawere able to provide written informed consent
were considered eligible for the study. Speciﬁc
exclusion criteria are reported in the Online
Appendix. Patients were treated as per local stan-
dard of care, which included 325-mg aspirin LD and
4,000 IU of unfractioned heparin at time of patient
presentation. Access site, choice of anticoagulant,
and procedural technique were at the discretion
of the physician. As per institutional standards, the
LD of ticagrelor was administered immediately after
the procedure. Using a computer-based randomiza-
tion system, patients were randomly assigned
(1:1:1) to ticagrelor 180 mg (2 90-mg tablets), 270 mg (3
90-mg tablets), or 360 mg (4 90-mg tablets) LD. A
ticagrelor 90-mg bid maintenance dose was started
12 h after the LD; patients were recommended
to continue with this dosing regimen for at least
12 months. After PPCI, all patients received aspirin
81 mg indeﬁnitely.
Blood samples for PK and PD analysis were
collected at baseline (before PPCI) and at a total of
6 time points following study drug administration:
30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after LD (with a 
10% time window). A ﬂow diagram of the study
design is presented in Figure 1. In-hospital adverse
events, including ischemic events, bleeding, bra-
dyarrhythmias, and dyspnea, deﬁned according to
previously reported criteria in the PLATO (PLATelet
inhibition and patient Outcomes) trial (6), were
recorded. The study complied with the Declaration of
Helsinki, was approved by the Western Institutional
Review Board, and all patients gave their written
informed consent.
PK AND PD ASSESSMENTS. PK assessments included
determination of plasma concentration of ticagrelor
and its active metabolite (AR-C124910XX), as
previously described (2). Time for the maximal
plasma concentration (Tmax), maximal observed
plasma concentration (Cmax), and the area under
the plasma concentration versus time curve from time
0 to the last measurable concentration (AUC0-t) were
calculated. Dose-normalized Cmax and AUC0–t were
also calculated to assess the effects of morphine.acksonville, Jacksonville, Florida. The present study
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FIGURE 1 Study Design
LD ¼ loading dose; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction.
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1459PD assessments included the VerifyNow P2Y12
(Accriva Diagnostics, San Diego, California) andwhole-
blood vasodilator-stimulated phosphoprotein (VASP)
assays (Diagnostica Stago, Parsippany, New Jersey),
which were performed according to the manufac-
turer’s instructions, as previously described (4,10).
The VerifyNow P2Y12 assay reports results in P2Y12
reaction units (PRU). The VASP assay was used to
determine the platelet reactivity index (PRI) according
to standard protocols (4,10). High on-treatment
platelet reactivity (HPR) was deﬁned as a PRU >208
or a PRI >50% (10).
STATISTICAL ANALYSIS AND SAMPLE SIZE CALCU-
LATION. Conformity to the normal distribution
was evaluated for continuous variables with the
Kolmogorov-Smirnov test. For baseline characteris-
tics, continuous variables are expressed as mean 
SD or median (interquartile range), and categorical
variables are expressed as frequencies and percent-
ages. The chi-square test or the Fisher exact test was
used to compare categorical variables between
groups, whereas one-way analysis of variance or the
Kruskal-Wallis test were used to compare contin-
uous variables. An analysis of covariance methodFIGURE 2 Subject Disposition
CABG ¼ coronary artery bypass graft; GPI ¼ glycoprotein IIb/IIIa inhibitwith a general linear model, using the baseline value
of platelet reactivity and morphine use as covariates,
was used to evaluate all between-groups compari-
sons. A mixed between-within subjects analysis of
covariance with polynomial contrast, also adjusted
for baseline platelet reactivity and morphine use,or; other abbreviations as in Figure 1.






(n ¼ 15) p Value
Age, yrs 60  8.6 58  8.5 57  12.1 0.664
Male 14 (87.5) 10 (66.7) 8 (53.3) 0.113
BMI, kg/m2 25.8  7.8 27.5  5.6 28.8  4.9 0.429
Race 0.774
Caucasian 11 (68.7) 12 (80) 11 (73.3)
African American 5 (31.3) 3 (20) 4 (26.7)
Hispanic/Asian 0 (0) 0 (0) 0 (0)
Hypertension 9 (56.3) 8 (53.3) 8 (53.3) 0.671
Diabetes mellitus 5 (31.3) 3 (20) 2 (13.3) 0.472
Dyslipidemia 9 (56.3) 9 (60) 5 (33.3) 0.284
Active smoking 8 (50) 11 (73.3) 5 (33.3) 0.088
Prior CAD 2 (12.5) 3 (20) 1 (6.7) 0.554
Prior MI 1 (6.3) 2 (13.3) 1 (6.7) 0.739
Prior stroke 1 (6.3) 0 (0) 0 (0) 0.384
LVEF, % 57.9  10 53.8  12 52.4  14 0.479
Creatinine, mg/dl 0.93  0.13 0.87  0.2 1.0  0.25 0.352
GFR, ml/min 98  34 100  28 95  26 0.925
Platelet count, 103/ml 261  96 237  85 236  82 0.712
Hematocrit, % 39.9  5.7 42.2  5.1 41.8  4.2 0.483
Hemoglobin, g/dl 13.4  2.2 14.3  1.8 14.2  1.7 0.402
Door-to-balloon, min 52.5 [45.7–66] 54 [44–109] 56.5 [40.5–68.5] 0.385
Location of MI 0.449
Anterior 4 (25) 4 (26.7) 6 (40)
Inferior 11 (68.7) 11 (73.3) 7 (46.7)
Other 1 (6.3) 0 (0) 2 (13.3)
Culprit lesion 0.600
LAD 4 (25) 4 (26.7) 6 (40)
RCA 9 (56.3) 5 (33.3) 6 (40)
LCX 3 (18.8) 5 (33.3) 3 (20)
Vein graft 0 (0) 1 (6.7) 0 (0)
Arterial access 0.547
Femoral 10 (62.5) 12 (80) 10 (66.7)
Radial 6 (37.5) 3 (20) 5 (33.3)
TIMI ﬂow grade 0 pre-PCI 11 (68.8) 10 (66.7) 12 (80) 0.359
Stent type 0.828
DES 14 (87.5) 13 (86.7) 12 (80)
BMS 0 (0) 1 (6.7) 1 (6.7)
POBA 2 (12.5) 1 (6.7) 2 (13.3)
Stent length, mm 25.9  14.5 22.2  9.1 24.6  18.5 0.696
Medications*
Aspirin 16 (100) 15 (100) 15 (100) 1
Insulin therapy 3 (18.8) 0 (0) 1 (6.7) 0.170
OAD 2 (12.5) 2 (13.3) 2 (13.3) 0.997
Beta-blockers 14 (87.5) 12 (80.0) 14 (93.3) 0.554
ACE-I/ARB 14 (87.5) 11 (73.3) 14 (93.3) 0.291
Statins 16 (100) 15 (100) 15 (100) 1
PPI 1 (6.3) 5 (33.3) 5 (33.3) 0.122
Morphine 2 (12.5) 4 (26.7) 10 (66.7) 0.005
IV anticoagulant 0.746
Bivalirudin 13 (81.2) 14 (93.3) 14 (93.3)
UFH 3 (18.8) 1 (6.7) 1 (6.7)
Values are mean  SD, n (%), or median [interquartile range]. *Within 24 h from admission.
ACE-I¼ angiotensin-convertingenzyme inhibitors; ARB¼ angiotensin receptorblockers; BMI¼bodymass index;
BMS¼bare-metal stent; CAD¼ coronary arterydisease; DES¼drug-eluting stent; GFR¼ glomerularﬁltration rate;
IV ¼ intravenous; LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery; LD ¼
loading dose; LVEF ¼ left ventricular ejection fraction; MI ¼myocardial infarction; OAD ¼ oral antidiabetic drugs;
PCI ¼ percutaneous coronary intervention; POBA ¼ plain old balloon angioplasty; PPI ¼ proton pump inhibitor;
RCA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction; UFH ¼ unfractioned heparin.
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1460was conducted with a general linear model to eval-
uate the overall difference between groups across
time points. A repeated measures analysis of vari-
ance model was used to evaluate intragroup com-
parisons. The Bonferroni approach was used to
correct for multiple comparisons (11). A multivariable
analysis to evaluate the presence of baseline char-
acteristics independently associated with HPR at
1, 2, and 4 h was performed by a binomial logistic
regression analysis. A 2-tailed p value of <0.05 was
considered to indicate a statistically signiﬁcant dif-
ference for all the analyses performed. Results are
reported as least-square mean  SE for the above
detailed analyses. Statistical analysis was performed
using SPSS version 22.0 software (SPSS, Chicago,
Illinois).
The primary endpoint of the study was the level of
platelet reactivity measured by VerifyNow P2Y12 (i.e.,
PRU) comparing 180-mg versus 360-mg ticagrelor LD
at 1 h after administration. Assuming a 30% differ-
ence in the PRU between the 2 arms after ticagrelor
LD with a standard deviation of 63 PRU, 15 patients
need to be enrolled in each arm to obtain a 90% power
and 2-sided alpha ¼ 0.05. Considering the 3 arms of
treatment and a possible dropout of approximately
15% to 20%, we estimated that a total of 52 patients
needed to be randomized to ensure that complete
data would be available for analysis. The sample size
of our study was calculated according to published
data available at the time of our study design (3,8).
Further details on statistical analysis are provided in
the Online Appendix.RESULTS
PATIENT POPULATION. Between September 2013
and June 2014, there were a total of 129 STEMI
activations; of these, 52 patients provided their
written informed consent to participate in the study
and were randomized, representing the treated
population. A total of 46 patients (180 mg, n ¼ 16;
270 mg, n ¼ 15; 360 mg, n ¼ 15) met criteria for in-
clusion in the primary population. Patient disposition
is summarized in Figure 2. Baseline characteristics are
summarized in Table 1 and were similar between
groups, except for the use of morphine, which was
higher in patients in the 360-mg LD group (p ¼ 0.005).
One patient in the 270-mg group had an ischemic
stroke. The rate of any in-hospital bleeding was 7.7%.
Details about adverse events are provided in the
Online Appendix.
PHARMACODYNAMIC ASSESSMENTS. Baseline PRU
values (p ¼ 0.973) were similar among groups. There
FIGURE 3 Pharmacodynamic Assessment Following Administration of Escalating
Ticagrelor LD Regimens
(A) P2Y12 reaction units (PRU) measured by the VerifyNow P2Y12 assay. §270 mg versus
360 mg, p ¼ 0.026; 180 mg versus 270 mg, p ¼ 0.087; 180 mg versus 360 mg, p >
0.999. (B) Platelet reactivity index (PRI) measured by the vasodilator stimulated phos-
phoprotein (VASP) assay. †270 mg versus 360 mg, p ¼ 0.060; 180 mg versus 270 mg, p ¼
0.496; 180 mg versus 360 mg, p ¼ 0.706. Values are expressed as least-square means.
Error bars indicate standard error. LD ¼ loading dose.
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1461was a marginally signiﬁcant interaction between
treatment group and time (Wilks Lambda p ¼ 0.043).
Following ticagrelor LD administration, PRU levels
signiﬁcantly decreased over time in all groups (p <
0.001 for all LD regimens). During the overall 24-h
study time course, PRU levels were reduced to a
similar extent irrespective of LD regimen, as
assessed in both an unadjusted analysis (p ¼ 0.137)
and after adjusting for baseline PRU values and
morphine use (p ¼ 0.179) (Figure 3A). There were no
signiﬁcant differences in PRU levels among groups at
all time points (p > 0.1), with the exception of at 1 h
(p ¼ 0.017). In particular, at 1 h, PRU levels were
signiﬁcantly lower using a 270-mg LD regimen
compared with a 360-mg regimen (p ¼ 0.026) and
nonsigniﬁcantly lower than a 180-mg regimen
(p ¼ 0.087); there was no difference between the 180-
mg and 360-mg groups (primary endpoint; p > 0.999).
Parallel ﬁndings were observed with VASP-PRI.
VASP-PRI levels were similar among groups during
the overall 24-h study time course in the unadjusted
analysis (p ¼ 0.949) and after adjusting for baseline
PRI values and morphine use (p ¼ 0.974) (Figure 3B).
There were no signiﬁcant differences in VASP-PRI
levels among the 3 LD regimens at any of the study
time points; only a trend across groups was observed
1 h after LD (p ¼ 0.060).
HIGH ON-TREATMENT PLATELET REACTIVITY. Rates of
HPR assessed by VerifyNow P2Y12 were high during
the ﬁrst 2 h after LD administration. In particular,
HPR was observed in 50% of patients at 1 h after LD
administration in the overall study population
(Figure 4A). At this time point, HPR rates were
signiﬁcantly different among the groups (p ¼ 0.038).
Patients in the 270-mg group had lower HPR rates
(26.7%) compared with those in the 180-mg (50%) and
360-mg (73.3%) LD groups. At 2 h, HPR was observed
overall in 30.4% of patients following LD adminis-
tration. HPR rates were numerically lower in the
180-mg group, although there were no signiﬁcant
differences among the LD groups (p ¼ 0.419). The
overall rate of HPR at 4 h was 8.7%. HPR was
numerically higher in the 180-mg group (18.8%)
compared with the 270-mg (6.7%) and 360-mg groups
(0%). At 8 and 24 h after LD, the rates of HPR were
low (ranging from 0% to 7.7%) and similar among the
different LD regimens (Figure 4A). After multivariable
analysis, the only independent predictor of HPR
assessed by VerifyNow P2Y12 was the use of
angiotensin-converting enzyme (ACE) inhibitors/
angiotensin receptor blockers (ARBs), which was
signiﬁcantly associated with the absence of HPR at 2 h(odds ratio: 0.022; 95% conﬁdence interval: 0.001 to
0.552; p ¼ 0.020).
HPR rates as assessed by VASP-PRI showed a similar
trend to PRU (Figure 4B). At 1 h following LD adminis-
tration, HPR rate was 65% in the overall study popu-
lation. There were signiﬁcant differences among the
LD groups (p ¼ 0.034). Patients in the 270-mg group
experienced a lower rate of HPR (38.5%) compared
with those in the 180-mg (68.8%) and 360-mg (85.7%)
groups. At 2 h, HPR rate was 37.2% in the overall study
population. HPR was numerically lower in the 180-mg
FIGURE 4 Rates of HPR Following Administration of Escalating Ticagrelor
LD Regimens
(A) High on-treatment platelet reactivity (HPR) rates as assessed by the VerifyNow P2Y12
assay. §270mg versus 360mg, p¼0.081; 180mg versus 270mg, p¼0.819; 180mg versus
360mg, p¼ 0.819. (B)HPR rates as assessed by the vasodilator stimulated phosphoprotein
(VASP) assay. †270mgversus 360mg, p¼0.054; 180mgversus 270mg, p¼0.432; 180mg
versus 360 mg, p > 0.999. Histograms represent rates. LD ¼ loading dose.
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1462and 270-mg groups compared with the 360-mg group,
though this difference was not signiﬁcant (p ¼ 0.483).
The overall rate of HPR at 4 h was 18.6% and was
numerically higher in the 360-mg group (28.6%)
compared with the 180-mg (20%) and 270-mg groups
(7.1%). At 8 and 24 h after LD, the rates of HPR were
lower (ranging from 0% to 14.3%) and overall similar
among dosing regimens (Figure 4B). After multivari-
able analysis, we found no independent predictors of
HPR assessed by VASP. The rates of patients experi-
encing HPRwith both assays were approximately 66%,40%, 30%, 7%, 2.5%, and 0% at 30min, 1 h, 2 h, 4 h, 8 h,
and 24 h after LD, respectively.
PHARMACOKINETIC ASSESSMENT. Following tica-
grelor LD administration, ticagrelor absorption was
delayed irrespective of dose, with mean ticagrelor
Tmax ranging from 3.9 h in the 180-mg group to 7.1 h
in the 360-mg group. Accordingly, generation of
the active metabolite AR-C124910XX was also delayed
for all 3 ticagrelor LD regimens tested, with a mean
Tmax of 6.3 to 9.1 h (Table 2). Exposure to ticagrelor
and AR-C124910XX, measured as Cmax and AUC0–t,
increased only with the dosing regimen escalating
from 180 mg to 270 mg, whereas merely a minimal
increase was observed when escalating from 270 mg
to 360 mg (Table 2).
The mean plasma concentrations of ticagrelor were
higher in the 270-mg group at 30 min and 1 h following
LD, whereas at 2 h, the highest mean plasma con-
centration was achieved by the 180-mg LD. At 4 h and
through the ﬁnal time point, the 360-mg group ach-
ieved higher plasma concentrations compared with
the 180-mg and 270-mg groups (Figure 5A). The mean
plasma concentrations of the active metabolite AR-
C124910XX showed a similar trend (Figure 5B).
Compared with non-HPR patients, those with HPR at 1
and 2 h showed a delay in peak plasma concentrations
of ticagrelor (Figures 6A and 6B). Parallel ﬁndings
were observed with AR-C124910XX (data not shown).
During the overall study time course, platelet reac-
tivity values strongly correlated with plasma levels
of ticagrelor (PRU: rS ¼ 0.733, p < 0.001; PRI:
rS ¼ 0.800, p < 0.001) and AR-C124910XX (PRU:
rS ¼ 0.756, p < 0.001; PRI: rS ¼ 0.785, p < 0.001).
IMPACT OF MORPHINE ON PD AND PK ASSESSMENTS.
A total 16 of 46 (34.7%) patients received morphine,
which was administered at the time of clinical pre-
sentation and before ticagrelor LD administration.
PRU levels following ticagrelor LD were similar be-
tween patients receiving and not receiving morphine
during the overall 24-h time course in the unadjusted
analysis (p ¼ 0.412) and after adjusting for baseline
PRU values (p ¼ 0.262). There was no signiﬁcant
interaction between treatment group and time (Wilks
Lambda p ¼ 0.110). PRU levels were signiﬁcantly
higher at 30 min following LD (p ¼ 0.018) and
nonsigniﬁcantly higher at 1 (p ¼ 0.185) and 2 h (p ¼
0.145) in patients treated with morphine. PRU values
assessed at all other study time points were not
signiﬁcantly different between groups (Figure 7A).
These ﬁndings translated into higher rates of HPR in
patients treated with morphine in the ﬁrst 2 h
following LD administration compared with patients
TABLE 2 Pharmacokinetic Proﬁles of Ticagrelor and Its Active Metabolite








Tmax, h 3.9 (2.0–24) 5.0 (1.0–24) 7.1 (2.0–24)
AUC0-t, ng  h/ml 7,893 (1,270–33,974) 12,379 (2,935–33,105) 12,381 (768–66,201)
Cmax, ng/ml 789 (95–3,550) 1,208 (276–2,940) 1,208 (242–4,040)
AR-C124910XX
Tmax, h 6.3 (2.0–24) 6.7 (1.0–24) 9.1 (2.0–24)
AUC0–t, ng  h/ml 3,216 (1,146–7,252) 4,375 (1,135–12,241) 4,455 (315–16,029)
Cmax, ng/ml 239 (125–502) 376 (235–785) 370 (123–1,290)
Values are geometric mean (range).
AUC0-t ¼ area under the plasma concentration vs. time curve from time 0 to the last measurable concentration;
Cmax ¼ maximum observed plasma concentration; LD ¼ loading dose; Tmax ¼ time for the maximum plasma
concentration.
FIGURE 5 Pharmacokinetic Proﬁle of Ticagrelor and Its Major Active Metabolite
Following Administration of Escalating Ticagrelor LD Regimens
Plasma levels of ticagrelor (A) and its major active metabolite AR-C124910XX (B) during
the 24 h following administration of escalating loading doses (LD). Values are expressed as
mean. Error bars indicate standard error.
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1463not receiving morphine, although these differences
were not signiﬁcant (Figure 7B). Parallel ﬁndings were
observed with VASP-PRI (data not shown). After
multivariable analysis, morphine use was not found
to be an independent predictor of HPR.
The PK assessment showed lower mean plasma
concentrations of both ticagrelor and AR-C124910XX
during the ﬁrst 2 h following LD administration in
morphine-treated patients (Figures 7C and 7D).
Accordingly, in patients receiving morphine, tica-
grelor absorption was slightly delayed (mean Tmax 5.6
vs. 4.9 h) and formation of the active metabolite
AR-C124910XX was slower (mean Tmax 8.1 vs. 6.8 h)
compared with patients not receiving morphine.
Dose-normalized exposure to ticagrelor and AR-
C124910XX was lower in patients who received
morphine (Online Table 1).
DISCUSSION
The present study is the ﬁrst to investigate both the
PK and PD proﬁles of escalating LD of ticagrelor in the
setting of a prospective randomized study of patients
with STEMI undergoing PPCI. Our study conﬁrmed
that in the setting of STEMI, there is a delay in the
antiplatelet effect of ticagrelor leading to high rates of
HPR up to 4 h after LD administration. In particular,
at 1 and 2 h following LD, nearly one-half and one-
third of patients, respectively, still had levels of
platelet reactivity known to be associated with a
higher risk of thrombotic events. Importantly, such
PD ﬁndings persisted despite the use of escalating LD
regimens. Consistent results were observed using
2 different platelet function assays. Our PK assess-
ments conﬁrm that the mechanism leading to the
delayed antiplatelet effects of ticagrelor is a direct
result of impaired drug absorption, with Tmax values
which are signiﬁcantly longer in STEMI patients
compared with those reported in healthy subjects and
in patients with stable coronary artery disease, which
are approximately 1.5 to 2 h (2,12). In line with the PD
ﬁndings, our PK assessments indicate that the delay
in drug absorption was not dose-related, as it was
consistent with all LD regimens tested.
Adjunctive therapy with a platelet P2Y12 receptor
inhibitor is pivotal for reduction of thrombotic risk in
patients with acute coronary syndrome (1). However,
PD studies have shown suboptimal platelet inhibition
in the early hours after LD administration in STEMI
patients undergoing PPCI (8,9). In addition to the
enhanced prothrombotic status, other common fea-
tures in patients with STEMI are hemodynamic
instability, adrenergic activation, systemic vaso-
constriction, pharmacotherapy, abnormal muscular
FIGURE 6 Pharmacokinetic Proﬁles of Patients With HPR Following Administration of
Ticagrelor LD
Plasma levels of ticagrelor during the 24 h following loading dose (LD) administration in
patients with high on-treatment platelet reactivity (HPR) compared with non-HPR patients
at 1 h (A) and 2 h (B). Patients randomized to different dosing regimens are pooled
together. Values are expressed as mean. Error bars indicate standard error.
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vomiting, which in turn can lead to impaired intesti-
nal absorption and hepatic metabolism (9,13). Our
study demonstrated that this delay in the antiplatelet
effect of ticagrelor is mainly attributed to an altered
PK proﬁle (“drug exposure”), with impaired absorp-
tion in the early hours after drug administration, and
not to platelet dysfunction (“drug response”). This is
further demonstrated by the presence of extremely
low plasma concentrations of ticagrelor and AR-
C124910XX in the ﬁrst 2 h after LD in patients with
HPR. In our study, we found that the only indepen-
dent predictor of HPR was the use of ACE inhibitors/ARBs, which was independently associated with the
absence of HPR at 2 h assessed by VerifyNow. How-
ever, because this association was shown only with
1 assay and only at 2 h, these observations are most
likely due to play of chance.
Because ticagrelor is a direct-acting agent that
has a dose-dependent PK proﬁle in healthy volun-
teers (2), the use of higher LD regimens has been
advocated in STEMI patients undergoing PPCI. In
a nonrandomized PD comparison of STEMI patients
undergoing PPCI, Alexopoulos et al. (14) showed
that a high LD of ticagrelor (360 mg) was not
associated with enhanced platelet inhibition or
reduction in HPR rates compared with a standard
LD (180 mg). In another study by Parodi et al. (15), a
high LD of ticagrelor (360 mg) was not associated
with enhanced platelet inhibition compared with a
standard LD of prasugrel (60 mg), though a stan-
dard ticagrelor LD arm was not tested. Our study
expands upon these ﬁndings by conducting a more
comprehensive PK and PD investigation in the
setting of a prospective randomized dose-escalation
trial.
Although we showed that a 270-mg LD achieved
higher platelet inhibition in the ﬁrst hour after LD,
signiﬁcant differences were only observed with 1 PD
assay. Surprisingly, in the ﬁrst 2 h following LD, the
lowest antiplatelet effect was observed with the
360-mg LD. These ﬁndings were paralleled by PK
proﬁles that showed a prolonged Tmax and no mean-
ingful increase in drug exposure compared with a
270-mg LD. This may be in part attributed to the
higher use of morphine in this group. In fact,
morphine is known to inhibit gastric emptying and
oral–cecal transit time, leading to delayed absorption
and potentially decreasing peak plasma levels of
orally administered drugs (16). In a study of healthy
volunteers, morphine has shown to also impair clo-
pidogrel absorption and reduce plasma levels of its
active metabolite, which translated into delayed and
hampered PD effects (17). Moreover, a post-hoc anal-
ysis of PD studies also showed morphine as a possible
cause of delayed P2Y12 inhibition in STEMI patients
undergoing PPCI treated with either prasugrel or
ticagrelor (18). Most recently, pre-hospital adminis-
tration of ticagrelor LD did not improve markers of
pre-PCI coronary reperfusion compared with in-
hospital administration in STEMI patients; levels of
platelet reactivity were also similar between the 2
strategies (19). In this trial, pre-hospital administra-
tion allowed a median time difference of only 31 min
compared with in-hospital administration. Thus, the
results of our study, showing a minimal PK and PD
effect of ticagrelor at 30 min after LD, provide
FIGURE 7 Pharmacodynamic and Pharmacokinetic Proﬁle of Ticagrelor Following LD Administration According to Morphine Use
(A) P2Y12 reaction units (PRU) measured by the VerifyNow P2Y12 assay comparing patients who received morphine versus patients who did not receive morphine.
(B) High on-treatment platelet reactivity (HPR) rates as assessed by the VerifyNow P2Y12 assay comparing patients who received morphine versus patients who did not
receive morphine. Plasma levels of ticagrelor (C) and (its major active metabolite AR-C124910XX [D]) during the 24 h following administration of loading dose (LD) in
patients who received morphine versus patients who did not receive morphine. Patients randomized to different dosing regimens are pooled together. In A, values are
expressed as least-square means. Error bars indicate standard error. In B, histograms represent rates. In C and D, values are expressed as means. Error bars indicate
standard error.
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1465potential mechanistic insights on why the trial did not
meet its primary endpoint. However, a signiﬁcant
interaction between morphine use and the time of
ticagrelor administration was observed on pre-PCI
coronary reperfusion, which may have affected the
overall trial results (19). Consistent with these ﬁnd-
ings, in our study, morphine signiﬁcantly altered the
PK proﬁles of ticagrelor resulting in delayed drug ab-
sorption and lower PD effects in the early hours
following LD. However, the above results need to be
interpreted as hypothesis generating since these were
post-hoc assessments conducted in a subgroup.
Moreover, in our study, morphine use was not found
to be an independent predictor of HPR. Indeed, spe-
ciﬁcally designed randomized prospective in-
vestigations exploring the role of morphine areneeded to better clarify its effect on the PK/PD proﬁles
of ticagrelor.
The ﬁndings that a considerable number of STEMI
patients have levels of platelet reactivity above
thresholds associated with thrombotic events even
after doubling the LD regimen of ticagrelor, under-
score the need for strategies aimed to achieve more
optimal platelet inhibition particularly in the early
hours after PPCI. The use of potent intravenous
antiplatelet agents, prolonging bivalirudin infusion
and crushing of oral antiplatelet tablets to facilitate
gastrointestinal absorption may help overcome this
issue (7,20–23).
STUDY LIMITATIONS. Our study was not powered to
assess safety or efﬁcacy, which would require larger
PERSPECTIVES
WHAT IS KNOWN? Pharmacodynamic studies
assessing oral P2Y12 inhibitors, including ticagrelor,
have shown a delay in platelet inhibitory effects in
patients with ST-segment elevation myocardial
infarction undergoing primary percutaneous coronary
intervention. In turn, a considerable number of pa-
tients persist with inadequate platelet inhibition in the
early hours after loading dose administration sug-
gesting the need for higher dosing regimens.
WHAT IS NEW? The impaired response to ticagrelor
in the early hours after drug administration in patients
undergoing primary percutaneous coronary interven-
tion cannot be overcome by increasing loading dose
regimens. This delay in the antiplatelet effect is
mainly attributed to an altered pharmacokinetic pro-
ﬁle (“drug exposure”), with reduced absorption in the
early hours after drug administration.
WHAT IS NEXT? There is need for further studies
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1466clinical studies. Hence, the lack of difference in
adverse events between dosing regimens, including
bleeding complications, found in this study should
be interpreted with caution. Although laboratory
personnel were blinded to treatment assignment,
the study had an open-label design. The adminis-
tration of morphine was left at the discretion of the
treating physician and in our study, its use was not
balanced between groups. Although avoiding the use
of morphine could have represented a strategy to
overcome this limitation, at the time of study
design, the impact of morphine on PD response
proﬁles was unknown. Moreover, in line with
guideline recommendations, morphine is broadly
utilized in the treatment of STEMI patients, as was
also shown in other studies (9,18,19). Further, all
PD comparisons were adjusted for morphine use,
and morphine was not an independent predictor of
impaired drug response at multivariable analysis.
Importantly, the PD and PK proﬁles of ticagrelor
were also compromised in patients not receiving
morphine. However, we cannot rule out that a larger
sample size would have resulted in a more homog-
enous distribution of morphine use and in different
results about its inﬂuence on the PK and PD proﬁles
of ticagrelor. Therefore, our study observations on
morphine should be considered exploratory and
hypothesis generating for dedicated trials. The
sample size of our study was calculated according to
published data available at the time of our study
design (3,8). Subsequent studies have shown that
the PD differences of increasing ticagrelor LD were
actually lower, making our study underpowered (14).
Therefore, we cannot exclude that a larger popula-
tion would have resulted in different study ﬁndings.
Finally, our study was not powered to evaluate in-
dependent predictors of HPR, which would require
larger samples.aimed to identify strategies to achieve more optimal
platelet inhibition in the early hours after primary
percutaneous coronary intervention, such as the use
of potent intravenous antiplatelet agents and crush-
ing of oral antiplatelet tablets to facilitate gastroin-
testinal absorption.CONCLUSIONS
Patients with STEMI undergoing PPCI exhibit
reduced response to ticagrelor in the early hours after
drug administration. The use of increased LD regi-
mens of ticagrelor did not overcome this delayedantiplatelet effect. These PD ﬁndings are largely
attributed to an impaired PK proﬁle as a consequence
of a delay in drug absorption, as compared with that
reported in stable clinical conditions. The results of
this PK/PD investigation underscore the need for
further studies aimed to identify strategies which
will achieve more optimal platelet inhibition in the
early hours following PPCI procedures in patients
with STEMI.
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